Jacobio’s Pharmaceuticals Group’s Hong Kong IPO

O’Melveny & Myers LLP advised Jacobio Pharmaceuticals Group Co. LTD on the deal.

Jacobio Pharmaceuticals Group Co. Ltd announced its IPO and listing on the Hong Kong Stock Exchange. The IPO offering size was approximately HK$1.35 billion (approximately US$174 million), prior to the exercise of the over-allotment option. Assuming full exercise of the over-allotment option, the offering size will be approximately HK$1.55 billion (approximately US$200 million).

Established in July 2015, Beijing-based Jacobio is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology and other therapies. Jacobio has entered into a global strategic collaboration with AbbVie to develop and commercialize the SHP2 inhibitors of Jacobio on a global basis, including the Core Product of Jacobio.

O’Melveny advised Jacobio on both Hong Kong and United States laws, and was the chief drafter of the prospectus. Goldman Sachs and CICC were the joint sponsors and joint global coordinators.

The O’Melveny team was led by partners Ke Geng (Picture) and Ke Zhu, and included counsel Yiming Liu, Wendy Kan, and Wei Liu, and associates Xiaoyu Xu, Yiying Wang, Henry Wong, and Qianru Hong.

Involved fees earner: Ke Geng – O’Melveny & Myers LLP; Qianru Hong – O’Melveny & Myers LLP; Wendy Kan – O’Melveny & Myers LLP; Yiming Liu – O’Melveny & Myers LLP; Wei Liu – O’Melveny & Myers LLP; Yiying Wang – O’Melveny & Myers LLP; Henry Wong – O’Melveny & Myers LLP; Xiaoyu Xu – O’Melveny & Myers LLP; Ke Zhu – O’Melveny & Myers LLP;

Law Firms: O’Melveny & Myers LLP;

Clients: Jacobio Pharmaceuticals Co., Ltd;


Author: Michael Patrini